Written Communication Relating to an Issuer or Third Party (sc To-c)
June 29 2016 - 5:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
(Rule 13e-4)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
Accretive
Health, Inc.
(NAME OF SUBJECT COMPANY (ISSUER) AND FILING PERSON (OFFEROR))
Common Stock, $0.01 par value
(TITLE OF CLASS OF SECURITIES)
00438V 103
(CUSIP NUMBER
OF CLASS OF SECURITIES)
Accretive Health, Inc.
401 North Michigan Avenue
Suite 2700
Chicago,
Illinois 60611
Attention: Corporate Secretary
(312) 324-7820
(NAME,
ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE
NOTICES AND COMMUNICATIONS ON BEHALF OF THE FILING PERSON)
COPY TO:
Robert
M. Hayward, P.C.
Kirkland & Ellis LLP
300 North LaSalle
Chicago, Illinois 60654
CALCULATION
OF FILING FEE
|
|
|
|
|
TRANSACTION VALUATION
|
|
AMOUNT OF FILING FEE*
|
|
N/A
|
|
N/A
|
|
|
|
*
|
Pursuant to General Instruction D to Schedule TO, a filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.
|
|
¨
|
Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the
Form or Schedule and the date of its filing.
|
|
|
|
|
|
|
|
|
|
Amount Previously Paid:
|
|
N/A
|
|
Filing party:
|
|
N/A
|
|
Form or Registration No.:
|
|
N/A
|
|
Date Filed:
|
|
N/A
|
|
x
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates:
|
|
|
¨
|
third-party tender offer subject to Rule 14d-1
|
|
|
x
|
issuer tender offer subject to Rule 13e-4
|
|
|
¨
|
going private transaction subject to Rule 13e-3
|
|
|
¨
|
amendment to Schedule 13D under Rule 13d-2
|
Check the following box if the filing is a final
amendment reporting the results of the tender offer:
¨
If applicable, check
the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
|
|
¨
|
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
|
|
|
¨
|
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
|
On June 29, 2016, Accretive Health, Inc. (“Accretive Health” or the
“Company”) announced to certain employees that its board of directors has approved, subject to approval by the Company’s stockholders, a stock option exchange program for employees (the “Proposed Stock Option Exchange
Program”). In connection with the Proposed Stock Option Exchange Program, the Company is herewith filing a slide presentation dated June 29, 2016, used by the Company’s President and Chief Executive Officer, Joseph Flanagan, in
conjunction with a conference call with such employees outlining the Proposed Stock Option Exchange Program.
The communication
attached as an exhibit to this Schedule TO does not constitute an offer to holders of the Company’s outstanding stock options to exchange those options. The Proposed Stock Option Exchange Program will only be consummated, if commenced at all,
if the Company’s stockholders approve the Proposed Stock Option Exchange Program.
The Stock Option Exchange Program
has not yet commenced. The Company will file a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission (“SEC”) upon the commencement of the Stock Option Exchange Program. Persons who are eligible to participate in
the Stock Option Exchange Program should read the Tender Offer Statement on Schedule TO and other related materials when those materials become available, because they will contain important information about the Stock Option Exchange Program.
In connection with the proposal to be voted on by the Company’s stockholders to approve the Stock Option Exchange
Program, the Company intends to file a preliminary proxy statement with the SEC and intends to file other relevant materials with the SEC, including a definitive proxy statement. The Company’s stockholders are urged to read such materials as
and when they become available and before making any voting decision regarding the Stock Option Exchange Program, because they will contain important information about the proposal to be voted on by stockholders with respect to the Stock Option
Exchange Program.
The Company’s stockholders and option holders will be able to obtain the written materials described
above and other documents filed by the Company with the SEC free of charge from the SEC’s website at
www.sec.gov
. In addition, stockholders and option holders may obtain free copies of the documents filed by the Company with the SEC by
directing a written request to: Accretive Health, Inc., Attention: Office of Investor Relations, 401 North Michigan Avenue, Suite 2700, Chicago, Illinois 60611.
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Slide presentation dated June 29, 2016, used by Joseph Flanagan in conjunction with a conference call with certain employees outlining the Proposed Stock Option Exchange Program.
|
R1 RCM (NASDAQ:RCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
R1 RCM (NASDAQ:RCM)
Historical Stock Chart
From Sep 2023 to Sep 2024
